Orbents is a Warsaw-based biotech venture dedicated to transforming rare disease treatment through advanced gene-editing technologies.
Millions of patients are underserved by traditional therapies — we bridge this gap with cutting-edge, accessible solutions. Our work combines rigorous science with human-focused innovation, targeting both medical breakthroughs and global healthcare equity.
Translating genetic science into real-world impact with pioneering therapies that drive innovation and reshape healthcare.
We design and refine advanced gene-editing techniques to address the unique biology of rare diseases, focusing on safety, efficacy, and scalability.
Development of targeted therapies for rare conditions
Ongoing clinical trials with patient-centric approaches
Our team builds a pipeline of next-generation therapies that prioritize affordability and access, ensuring breakthroughs are not limited to the few.
Collaborations with global research networks
End-to-end preclinical and clinical development strategies
We believe innovation must be inclusive. Our initiatives extend beyond labs to deliver sustainable solutions for underserved communities.
Partnerships with NGOs and patient groups
Programs to reduce treatment costs globally
We stand at the intersection of biotechnology and purpose. Our expertise in advanced gene-editing empowers us to target rare diseases with precision, affordability, and impact. We don’t just push scientific boundaries—we create accessible solutions that transform patient outcomes and build a healthier, more equitable future.
We leverage cutting-edge gene-editing technologies to develop targeted therapies, ensuring high efficacy and safety for rare disease patients.
Our solutions prioritize accessibility and affordability, putting patients and their needs at the heart of every project.
All rights reserved © 2025 Orbents